Solid organ transplant recipients are at risk for Pneumocystis carinii pneumonia (PCP), but the risk of PCP beyond 1 year is poorly defined. We identified 25 cases of PCP in 1,299 patients undergoing solid organ transplantation between 1987 and 1996 at The Cleveland Clinic Foundation (4.8 cases per 1,000 person transplant -years [PTY]). Ten (36%) of 28 PCP cases (transplantation was performed before 1987 in three cases) occurred §1 year after transplantation, and no patient developed PCP while receiving prophylaxis for PCP. The incidence of PCP during the first year following transplantation was eight times higher than that during subsequent years. The highest rate occurred among lung transplant recipients (22 cases per 1,000 PTY), for whom the incidence did not decline beyond the first year of transplantation. We conclude that the incidence of PCP is highest during the first year after transplantation and differs by type of solid organ transplant. Extending the duration of PCP prophylaxis beyond 1 year may be warranted for lung transplant recipients.
Solid organ transplant recipients are at increased risk for

Materials and Methods opportunistic infections including Pneumocystis carinii pneu-
Patients monia (PCP) [1, 2] . Seventeen percent of 583 cases of PCP in five large series of patients without AIDS occurred in solid
The Cleveland Clinic Foundation is a 934-bed tertiary care organ and bone marrow transplant recipients [3 -7] . Trimethomedical center and serves as one of the largest transplantation prim-sulfamethoxazole (TMP-SMZ) is highly effective in precenters in the United States. A total of 1,299 patients underwent venting PCP and is the agent of choice for chemoprophylaxis solid organ transplantations at The Cleveland Clinic Founda- [8, 9] . Primary prophylaxis is often discontinued within 12 tion between January 1987 and March 1996, including 534 months after transplantation because the risk of PCP is greatest renal transplantations (including 16 kidney-pancreas transplantations), 399 heart transplantations (including 5 heart-lung transplantations), 265 liver transplantations, and 101 lung transSee editorial response by Arend and van't Wout plantations. on pages 247 -9.
Case Definition in the first 6 months after transplantation [1, 10] . The occurrence of cases of PCP beyond 1 year after transplantation at
We included all cases of PCP occurring in any solid organ our institution prompted a retrospective review of cases of transplant patient at The Cleveland Clinic Foundation between PCP in solid organ transplant recipients to further define the January 1987 and March 1996. A diagnosis of PCP was estabappropriate duration of primary chemoprophylaxis.
lished by identification of compatible cysts in sputum, bronchoalveolar lavage (BAL) fluid, a transbronchial or open-lung biopsy specimen, or an autopsy specimen by using GrocottGomori methenamine -silver nitrate, toluidine blue, or modified Wright-Giemsa staining methods.
Clinical data abstracted from patient records included general demographic information, underlying immunosuppressing conditions, immunosuppressive drug regimens, methods of diagnosis, and the presence of additional pulmonary pathogens including bacteria, fungi, acid-fast organisms, or viruses.
Information was obtained regarding several aspects of the corticosteroid regimen utilized for immunosuppression. The dose of prednisone at time of diagnosis of PCP was noted. Previous dose-time relationships were classified by the methods used by Arend et al. [5] : continuous low dosage (õ30 mg/d for §1 month), continuous high dosage ( §30 mg/d for §1 month), and intermittent high dosage for rejection ( §500 mg/d for §2 days). Cumulative dose and total duration of prednisone therapy were also recorded. Data were collected regarding the clinical characteristics seen at presentation, the use of primary PCP prophylaxis, antipneumocystis treatment instituted, direct recipients; and dotted bars Å lung transplant recipients.
Primary PCP Prophylaxis for Solid Organ Transplant Recipients
the total number of cases was 28, of which 25 were used to calculate incidence and attack rates. The incidence rates of PCP Protocols for primary PCP prophylaxis for solid organ transwere measured in units of the reciprocal of person transplantplant recipients in the various transplant groups were not uniyears (PTY) calculated through March 1996. Incidence rates form during the study period: heart transplant recipients, one were subsequently stratified for the first year of transplantation double-strength tablet of TMP-SMZ was given every other day and the remainder of the follow-up period. for 6 months; lung transplant recipients, one double-strength tablet of TMP-SMZ was given daily for 1 year; and renal transplant recipients, one-half double-strength tablet of TMP-
Risk Factors for Survival
SMZ was given daily for 1 year. Notably, liver transplant Survivors of PCP were those patients who recovered from recipients did not routinely receive primary PCP prophylaxis the acute respiratory illness; nonsurvivors were those patients until 1992, following the occurrence of nine cases of PCP in who died of acute respiratory failure. Nonsurvivors were com-1990 and 1991 (figure 1). The current protocols for first-line pared with survivors to assess for any potential risk factors for PCP prophylaxis with TMP-SMZ at our institution are as folmortality, including serum lactate dehydrogenase (LDH) levels lows: heart-lung and lung transplant recipients, one doublemeasured within 3 days of the diagnosis of PCP, respiratory strength tablet thrice weekly indefinitely; liver transplant recipirate, serum albumin level, and resting arterial-alveolar oxygen ents, one double-strength tablet thrice weekly for 1 year; renal gradient (AaPO 2 ) at presentation. The normal range for LDH transplant recipients, one-half double-strength tablet daily for levels at our laboratory is 100 -220 U/L. the life of the allograft; and heart transplant recipients, one double-strength tablet every other day for 1 year.
Statistical Methods
All data were entered into a computerized database for analy-
Calculation of Rates of PCP
sis (EPI-Info, Version 6.02 [11] ). Student's t test and Fisher's The crude attack rates of PCP for each group of transplant two-tailed exact test were used for univariate analyses of the patients were determined by calculating the number of cases significance of associations. Multivariate logistic regression occurring in the study period divided by the total number of and Cox regression for association with mortality were done patients undergoing solid organ transplantation during the study by using PC SAS/STAT (SAS Institute, Cary, NC). Differences period. Three kidney transplant recipients who underwent were considered statistically significant at a P value of £.05. transplantation before 1987 and for whom PCP was diagnosed during the study period were included in the study but excluded Results from calculation of the incidence and attack rates of PCP. The intervals from transplantation to PCP for these three patients Twenty-eight cases of PCP were identified in solid organ transplant recipients, accounting for 30% of 92 cases of histowere 182, 575, and 832 weeks, respectively. For this reason,
01-20-99 06:05:01 cida UC: CID logically proven PCP in patients without AIDS at our institution were admitted to the hospital with a presumed infectious process, and a pneumonic process was initially suspected in 60%. during the 9-year study period (figure 1). The mean interval from the date of transplantation to the diagnosis of PCP was
The mean duration of symptoms before the diagnosis of PCP 20 weeks (range, 6 weeks to 16 years). Fifty-four percent (15) was 14 days, and the mean interval from admission to the of 28 solid organ transplant recipients developed PCP within diagnosis was 5.1 days. The diagnosis was made by BAL for 6 months of transplantation; 36%, §1 year after transplanta-86% (24) of the patients; transbronchial biopsies, 7% (2); and tion; and 21%, §2 years after transplantation.
open-lung biopsies, 7% (2). No patient developed PCP while receiving prophylaxis.
The most prevalent concomitant pulmonary infection was Eight solid organ transplant recipients (29%) had received prithat due to cytomegalovirus (CMV), which was isolated from mary PCP prophylaxis (all with TMP-SMZ) for a mean durathe BAL fluid from 36% (10) of 28 patients. Bacteria or fungi tion of 49 weeks (range, 6 to 312 months). The reasons for were isolated from BAL fluid from eight other patients, includdiscontinuation of TMP-SMZ prophylaxis included elevated creatinine level (1 patient), protocol (5), and unknown (2). The mean interval from the discontinuation of primary prophylaxis ing Staphylococcus species (2 patients), viridans streptococci died of other causes with those who died of PCP, we found that one risk factor was significantly associated with death: a (2), Candida species (3), and Aspergillus species (1).
higher mean serum LDH level at presentation (392 U/L vs.
U/L, respectively). A Cox regression model was used to
Patients with PCP ú1 Year After Transplantation assess the relationship of four continuous variables (serum LDH level, resting AaPO 2 , absolute lymphocyte counts, and The 11 patients developing PCP beyond 12 months after cell count in BAL fluid) with survival. The model suggested transplantation included 4 kidney transplant recipients, 3 that increasing serum LDH levels were associated with an inlung transplant recipients, 3 heart transplant recipients, and creased risk of mortality (P Å .06) (table 3). There was no 1 liver transplant recipient. The median interval from the relationship between survival and resting AaPO 2 , absolute lymtime of transplantation to PCP was 157 weeks (range, 64 phocyte counts, or cell count in BAL fluid. Those patients with weeks to 16 years). The clinical and laboratory findings for high serum LDH levels were at greater risk of death. For every these patients were similar to those for the 17 patients with increase of 100 U/L of serum LDH, the relative risk of death PCP during the first year following solid organ transplantanearly doubled (table 3). tion. All 11 patients were receiving prednisone therapy at the time of PCP (mean dosage, 18 mg/d); three (27%) were receiving tapering doses, and one (9%) was receiving in- the 9-year study period for the entire cohort of patients was estimated to be $121,560 by using the following assumptions: High doses of TMP-SMZ were given to 89% (25) of 28 $30 per year for TMP-SMZ therapy (thrice weekly) [9] and a patients as initial treatment for PCP. The remaining three patotal of 4,052 cumulative PTY for the 1,171 organ transplant tients were allergic to TMP-SMZ and were treated with penrecipients who survived the first year of transplantation. Theretamidine parenterally. A change in therapy was made for 10 fore, TMP-SMZ prophylaxis would be cost-effective from an patients because of drug allergy, drug toxicity, or therapeutic economic perspective if it prevents all cases of PCP. failure, including 32% (eight) of 25 patients receiving TMP-SMZ therapy. Corticosteroid therapy was given to 85% of patients during antipneumocystis treatment. Support with meDiscussion chanical ventilation was required for 21% of patients because of acute respiratory failure; two of these patients died.
The most important conclusions of our study are that the incidence of PCP among solid organ transplant recipients is Eight patients (29%) died within 30 days of the episode of PCP, of whom five died of PCP or related complications highest during the first year following transplantation and that no patient developed PCP while receiving primary prophylaxis. (including three of the 11 patients who had PCP after the first year of transplantation). Comparing survivors and patients who
Rates of PCP differed between types of transplant recipients.
/ 9c61$$fe43 01-20-99 06:05:01 cida UC: CID [8] 1988 -1989 7/17 (41) 0/7 NS Italy [18] 1985 -1991 7/241 (3) NS 14 (8 -48) Pittsburgh [13] 1981 -1986 5/92 (5) NS NS Spain [19] 1988 -1994 5/138 (3.6) 1/5 (20) 9 -17 South Africa [20] 1970 The highest incidence occurred among lung transplant recipicases occurred after the first year of transplantation [12, 13, 17, 20, 22, 29, 32, 35] . The organ-specific attack rates of PCP ents (22 cases per 1,000 PTY), for whom there was no decline in rates beyond 1 year of transplantation (in contrast to the ranged from a low of Ç4% among heart transplant recipients [8, 13, 16 -21] and renal transplant recipients [25 -35] to 11% other groups of solid organ transplant recipients) (table 1) .
Differences in attack rates of PCP between categories of among liver transplant recipients [22 -24] and 33% among heart-lung transplant recipients [15 -17, 35] . None of these solid organ transplant recipients have been suggested by previous studies of solid organ transplant recipients not receiving studies measured incidence rates as was done in our study, but there were two randomized prospective studies of primary PCP prophylaxis (table 4). The crude attack rate of primary PCP among 4,581 at-risk (no prophylaxis) solid organ transprophylaxis with TMP-SMZ vs. no prophylaxis for 58 heart transplant recipients [8] and 132 renal transplant recipients plant recipients was 4.9% (229 cases); most of these 229 cases occurred within 6 months of transplantation, although some [33] . It is interesting that the study of heart transplant recipients / 9c61$$fe43 01-20-99 06:05:01 cida UC: CID was prematurely terminated because of the high attack rate of A preemptive strategy of targeting indefinite PCP prophy-PCP among the control group (41% vs. 0 among patients relaxis to the 5% -10% of transplant recipients with recurrent or ceiving prophylaxis), whereas only one case of PCP occurred chronic rejection has been suggested [38] . The primary risk in the renal transplant patients (1.5% vs. 0 among patients for PCP (and other opportunistic infections) in solid organ receiving TMP-SMZ prophylaxis). transplant recipients is the ''net state of immunosuppression,'' The attributable mortality rate of 18% that we observed is to which a number of factors contribute, including the total slightly lower than the rate of 29% that was reported in prior amount of previous and current immunosuppressive treatments, studies (table 4) . The association we observed between serum the presence of acute and chronic graft rejection, and the pres-LDH level and prognosis of PCP in solid organ transplant ence of concomitant infections (especially those due to CMV) recipients has been previously described in studies of PCP in [10, 35, 45, 46] . Notably, 67% of our patients with PCP after patients with AIDS [36] .
the first year of transplantation had acute or chronic rejection There were limitations to our study that should be highat the time of PCP. We advocate targeting PCP prophylaxis lighted. Our case definition for PCP was very restrictive, and beyond 1 year of transplantation to those patients with recurrent it is possible that additional cases of PCP occurred that were or chronic rejection, and we favor indefinite prophylaxis for not histologically proven. Although incidence rates of PCP lung transplant recipients. for each transplant category could be measured, we could not measure incidence rates by PTY without prophylaxis because the protocols for primary prophylaxis for PCP were not stan-
